NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity RFA-HL-22-008 from the NIH Guide for Grants and Contracts. This FOA runs in parallel with the companion FOA (RFA-HL-22-007). This FOA uses the bi-phasic, milestone-driven UG3/UH3 cooperative agreement mechanism (UG3/UH3), and runs in parallel with a companion FOA (RFA-HL-22-008), which seeks applications for a Data Coordinating Center (DCC). Awards made under this FOA will support a milestone-driven planning phase, including feasibility studies and pilot trials for up to 2 years, with possible transition to an implementation phase (UH3) for up to five additional years. Only UG3 trials that meet the scientific milestones and award requirements of the UG3 phase may transition to the UH3 phase. Applications submitted in response to this FOA must address both the UG3 and UH3 phases. Applications must include plans for project management, subject recruitment and retention, scientific conduct of the trial including its design, randomization and power analysis; intervention, measurement, and statistical analysis of study results. Performance-based milestones must be included in each phase.
Funding Opportunity RFA-HL-22-007 from the NIH Guide for Grants and Contracts. This FOA uses the bi-phasic, milestone-driven UG3/UH3 cooperative agreement mechanism (UG3/UH3), and runs in parallel with a companion FOA (RFA-HL-22-008), which seeks applications for a Data Coordinating Center (DCC). Awards made under this FOA will support a milestone-driven planning phase, including feasibility studies and pilot trials for up to 2 years, with possible transition to an implementation phase (UH3) for up to five additional years. Only UG3 trials that meet the scientific milestones and award requirements of the UG3 phase may transition to the UH3 phase. Applications submitted in response to this FOA must address both the UG3 and UH3 phases. Applications must include plans for project management, subject recruitment and retention, scientific conduct of the trial including its design, randomization and power analysis; intervention, measurement, and statistical analysis of study results. Performance-based milestones must be included in each phase.
Funding Opportunity RFA-DK-21-005 from the NIH Guide for Grants and Contracts. This initiative will support the engineering of immune cells to target the human pancreatic compartment to report on previously inaccessible information about diabetes initiation and progression, and to deliver environment-specific therapeutic responses to restore islet health and prevent the progression to T1D.
Notice NOT-CA-21-036 from the NIH Guide for Grants and Contracts
Notice NOT-EY-21-001 from the NIH Guide for Grants and Contracts
Notice NOT-CA-21-040 from the NIH Guide for Grants and Contracts
Notice NOT-CA-21-039 from the NIH Guide for Grants and Contracts
Notice NOT-CA-21-038 from the NIH Guide for Grants and Contracts
Notice NOT-CA-21-037 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-CA-21-030 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) supports the development of cancer-relevant technologies suitable for use in low- and middle-income countries (LMICs). Specifically, the FOA solicits applications for projects to adapt, apply, and validate existing or emerging technologies into a new generation of user-friendly, low-cost technologies for preventing, detecting, diagnosing, and/or treating cancers in people living in LMICs. Applicants should have a working assay or device prototype (not necessarily already capable of cancer applications). The U01 project includes studies to both adapt this technology as well as demonstrate technical functionality and clinical performance for use of the device or assay in specific LMIC settings by meeting objective performance milestones followed by improvements and validations of the technologies in the LMIC settings. Projects proposed in response to this FOA will require multidisciplinary efforts to succeed; therefore, all applicant teams must include expertise in engineering/assay/treatment development, oncology, global healthcare delivery, and business development. Investigators responding to this FOA must consider affordability and cost-effectiveness as well as usability at the point-of-need as part of their design criteria. This funding opportunity is part of a broader NCI-sponsored Affordable Cancer Technologies (ACTs) Program.
Funding Opportunity RFA-AI-21-007 from the NIH Guide for Grants and Contracts. To support the design of novel tuberculosis (TB) vaccine candidates that exploit innovative approaches and their advancement into preclinical animal model testing. This funding opportunity will use a milestone driven, biphasic award mechanism to fund high risk/exploratory research. Transition to the second phase depends on the successful completion of milestones.
Funding Opportunity RFA-AI-21-022 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to provide an opportunity for the Regional Biocontainment Laboratories (RBLs) established by the National Institute of Allergy and Infectious Diseases (NIAID) to request support for upgrades to existing facilities and building systems to facilitate the conduct of biomedical research on infectious diseases, including infectious disease outbreaks.
Notice NOT-OD-21-067 from the NIH Guide for Grants and Contracts
Notice NOT-HG-21-022 from the NIH Guide for Grants and Contracts
Notice NOT-GM-21-031 from the NIH Guide for Grants and Contracts
Notice NOT-EB-21-004 from the NIH Guide for Grants and Contracts
Notice NOT-EB-21-005 from the NIH Guide for Grants and Contracts
Notice NOT-EB-21-002 from the NIH Guide for Grants and Contracts
Notice NOT-EB-21-003 from the NIH Guide for Grants and Contracts
Notice NOT-DK-21-013 from the NIH Guide for Grants and Contracts